Vanda Warning Letter From US FDA Leaves Firm "Puzzled"

The US FDA's warning letter to Vanda Pharmaceuticals Inc. seems relatively straightforward – the agency says the company included indications but not safety information when it listed its marketed products on its website – but the company says the correspondence actually raises a host of questions.

"We understand the words of the letter. What we are puzzled by is the reasoning for this action," Vanda CEO Mihael Polymeropoulos told the Pink Sheet in an interview. The confusion "comes in two flavors," he said